Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
08:42am, Tuesday, 22'nd Apr 2025
Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NVO 0.48%),
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
05:23am, Tuesday, 22'nd Apr 2025
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Down 60%, Is This Growth Stock Too Cheap to Ignore?
05:15am, Tuesday, 22'nd Apr 2025
In this video, I will cover recent updates regarding Novo Nordisk (NVO 0.48%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?
02:31am, Tuesday, 22'nd Apr 2025
Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. Lilly
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
06:50pm, Monday, 21'st Apr 2025
Novo Nordisk (NVO) closed the most recent trading day at $58.33, moving +0.43% from the previous trading session.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:05am, Monday, 21'st Apr 2025
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
09:15am, Monday, 21'st Apr 2025
Novo Nordisk (NVO -7.78%) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
09:00am, Monday, 21'st Apr 2025
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
08:30am, Monday, 21'st Apr 2025
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo
Selling America, Buying Europe - My Picks
09:15am, Sunday, 20'th Apr 2025
After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAP
Novo Nordisk: A Price Too Low To Ignore
10:52am, Friday, 18'th Apr 2025
Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappoint
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
03:28pm, Thursday, 17'th Apr 2025
BMO Capital Markets analyst Evan David Seigerman downgraded Novo Nordisk NVO from Outperform to Market Perform, lowering the price forecast from $105 to $64.
Rebecca Walser: Hold NVDA, Buy NVO & LRCX, Caution MCD
08:55am, Thursday, 17'th Apr 2025
Rebecca Walser (@walserwealth) joins Diane King Hall at the NYSE site with several specific stocks to highlight. On her current list of names she likes: Novo Nordisk (NVO) and Lam Research (LRCX).
Trump signs healthcare executive order that includes a win for pharma companies
05:43pm, Tuesday, 15'th Apr 2025
U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows Medicare to negotiate prescription drug prices, seeking to introduce a change
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
11:00am, Tuesday, 15'th Apr 2025
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
